D2C skincare brand Be Clinical has raised Rs 21 crore in a seed extension round led by Sauce. The company plans to use the funds to scale its in-house manufacturing and research capabilities. Founded in 2025, the brand focuses on evidence-based skincare, aiming to expand its market presence and product line amid intense competition in the personal care sector.
Direct-to-consumer skincare brand Be Clinical has successfully raised Rs 21 crore in a seed extension funding round. The investment was led by Sauce, a venture capital firm with a focus on consumer brands. Existing backer V3 Ventures also participated, alongside angel investors including the founders of Mokobara and executives from Reckitt.
The startup, which began operations in May 2025, plans to use this capital for specific growth initiatives. These include increasing manufacturing capacity, advancing research and development, and conducting further clinical testing. The company aims to move beyond its initial product lineup, which includes items like serums and eye creams, to enter new geographical markets.
In-House Manufacturing Strategy
A notable part of the company’s business model is its move to bring formulation and manufacturing processes in-house. While this strategy offers the company greater control over ingredient sourcing and product quality, it also introduces significant operational requirements. By moving away from outsourced manufacturing, the company takes on higher fixed costs and responsibilities for factory management and compliance.
For investors observing the D2C space, this shift represents a trade-off. In-house production can protect profit margins over the long term if managed well, but it also increases the amount of money the company must spend on facilities and equipment compared to brands that outsource their production. The success of this model will depend on the company's ability to keep its manufacturing lines efficient while maintaining consistent product quality.
Market Context and Competition
Be Clinical operates in the competitive Indian skincare market, where many established and new brands vie for consumer attention. The brand attempts to distinguish itself by focusing on clinical efficacy and longevity-focused skincare. The startup reports that it has fulfilled approximately 120,000 orders since its inception, providing a baseline for its current market traction.
This funding round follows a clear growth trajectory in the company’s fundraising history. Be Clinical initially raised Rs 2 crore in May 2025, followed by a Rs 6 crore round in January 2026. This rapid succession of funding rounds suggests that the company is currently in an aggressive expansion phase, which is common for startups attempting to capture market share quickly.
Risks and Monitorables
As a venture-backed startup, Be Clinical faces the standard risks associated with high-growth consumer businesses. The company remains dependent on future funding rounds to sustain its operations and expansion plans. If market conditions become difficult for consumer startups or if the company fails to hit its growth targets, it may face pressure to secure additional capital.
Moving forward, the primary monitorables for the company will be its cash burn rate and the actual demand for its products once it expands into new regions. The company's ability to maintain high quality in its in-house facilities while scaling up will be critical. Observers will also track whether the brand can sustain its growth in a market crowded with other well-funded competitors and if it can successfully translate its clinical focus into long-term customer loyalty.